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Background: Patients with COPD have had a lower tendency to quit smoking compared to 
patients with coronary heart disease (CHD). We wanted to investigate if this is still true in a 
Norwegian population.
Methods: Our data came from the fifth and sixth Tromsø surveys, which took place in 
2001–2002 and 2007–2008. The predictors of smoking cessation were evaluated in a cohort of 
4,497 participants who had stated their smoking status in both surveys.
Results: Of the 4,497 subjects in the cohort, 1,150 (25.6%) reported daily smoking in Tromsø 5. 
In Tromsø 6, 428 had quit (37.2%). A new diagnosis of obstructive lung disease (asthma or 
COPD) and CHD were both associated with increased quitting rates, 50.6% (P=0.01) and 
52.1% (P=0.02), respectively. In multivariable logistic regression analysis with smoking ces-
sation as outcome, the odds ratios (ORs) of a new diagnosis of obstructive lung disease and of 
CHD were 1.7 (1.1–2.7) and 1.7 (1.0–2.9), respectively. Male sex had an OR of 1.4 (1.1–1.8) 
compared to women in the multivariable model, whereas the ORs of an educational length of 
13–16 years and 17 years compared to shorter education were 1.6 (1.1–2.2) and 2.5 (1.5–4.1), 
respectively.
Conclusion: The general trend of smoking cessation in the population was confirmed. Increased 
rates of smoking cessation were associated with a new diagnosis of heart or lung disease, and 
obstructive lung disease was just as strongly linked to smoking cessation as was CHD. This 
should encourage the pursuit of early diagnosis of COPD.
Keywords: smoking cessation, cohort study, COPD, asthma, coronary heart disease
Background
Smoking cessation is crucial for a better prognosis in patients with coronary heart disease 
(CHD)1–3 and COPD.2,4,5 Acute heart attacks are associated with high smoking cessation 
rates. In patients with a first myocardial infarction (MI) in the 1970s,3 among whom 
78% were smoking, the quitting rate was 55%. In a systematic review from 2003, the 
mean rate of smoking cessation within a year after a new diagnosis of CHD was found 
to be 45%.1 A lower quitting rate was observed in patients with COPD, in particular 
in subjects not participating in smoking cessation programs. Among smoking COPD 
patients in a Swedish study, 10% of those receiving usual care had stopped smoking 
after 3 years, compared to 38% of those who took part in smoking cessation groups.6 
Among hospitalized patients with respiratory and cardiac diseases who took part in 
an intensive smoking cessation program in Singapore, 60% of the cardiac patients and 
40% of the respiratory patients were still abstinent from smoking after 2 months.7
The mortality due to CHD has decreased considerably in the Western world in the 
last few decades.8 Evidence shows that decreased smoking prevalence in the general 
population, particularly among patients with heart disease, is an important reason for 
Correspondence: hasse Melbye
general Practice research Unit, 
Mh-building, Department of Community 
Medicine, UiT The arctic University of 
norway, 9037 Tromsø, norway
email hasse.melbye@uit.no 
Journal name: International Journal of COPD
Article Designation: Original Research
Year: 2016
Volume: 11
Running head verso: Danielsen et al
Running head recto: New diagnosis and smoking cessation
DOI: http://dx.doi.org/10.2147/COPD.S108046
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
2.
14
8.
22
5.
20
1 
on
 2
5-
O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1454
Danielsen et al
this decrease.8–11 The mortality due to COPD has decreased 
less.12 A stronger tendency of persistent smoking among 
COPD patients may partly explain this difference.
COPD patients’ reluctance to quit smoking may lead to a 
feeling of hopelessness among the doctors who treat them.13 
Our aim was to determine how the quitting rate in adults is 
influenced by getting a diagnosis of obstructive lung disease 
in the population-based Tromsø study. We also wanted 
to investigate whether influence from this life event differs 
from being diagnosed with CHD.
Methods
subjects
A large proportion of the adult population in Tromsø has 
participated in health surveys (the Tromsø study) since 1974. 
Tromsø is a university city in northern Norway with ~72,600 
inhabitants. The Tromsø study so far consists of six surveys, 
and this study deals with subjects who participated in both 
Tromsø 5 (2001–2002) and Tromsø 6 (2007–2008). The 
attendance rates (of those invited) in Tromsø 5 and Tromsø 6 
were 79% and 66%, respectively. Details of the participants 
have previously been described.14 We included participants 
who answered the questions on smoking in both surveys. No 
smoking cessation support was offered during the surveys.
The Regional committee for Medical and Health Research 
Ethics and the Norwegian Data Inspectorate approved the 
Tromsø 5 and Tromsø 6 surveys with a license for further 
analysis on non-identifiable data, like this study. All the 
participants gave written informed consent.
examinations
In both surveys, the invitation included a questionnaire with 
questions on smoking habits, education, and diseases. We 
classified subjects reporting daily smoking in Tromsø 5, but 
not in Tromsø 6, as quitters. We divided length of education 
into three categories, 12 years, 13–16 years, and 17 years. 
Table 1 shows the reported diseases. For each disease in the 
questionnaire the participants were asked whether they have 
or have had the disease in question. We classified diseases 
reported in Tromsø 6 and not in Tromsø 5 as new diagnoses. 
We categorized MI and angina pectoris as “CHD” and asthma 
and COPD as “obstructive lung disease”.
statistical analysis
The frequencies of current smoking at baseline (in Tromsø 5) 
and smoking cessation among smokers were calculated by 
subject characteristics, and the statistical differences between 
subgroups were analyzed by chi-square statistics. We analyzed 
predictors of smoking cessation by binary logistic regression. 
Significant variables in univariable analysis (P0.1), as well 
as age and sex, were entered in the multivariable analysis. 
For the statistical analyses, we used the IBM SPSS statistic, 
Version 21 (IBM Corporation, Armonk, NY, USA).
Table 1 Daily smoking according to characteristics of the cohort 
of 4,497 participants in Tromsø 5 (2001–2002) who also took 
part in Tromsø 6 (2007–2008)
n Smoking, n (%) P-valuea
sex
Men 1,852 462 (24.9) 0.4
Women 2,645 688 (26.0)
age (years)
30–49 671 233 (34.7) 0.001b
50–69 2,879 733 (26.8)
70–81 947 144 (15.2)
education
0–12 years 3,265 869 (26.6) 0.001b
13–16 years 691 168 (24.3)
16 years 407 75 (18.4)
not answered 134 38 (28.3)
self-reported diseases
asthma
Yes 366 91 (24.9) 0.7
no 4,048 1,040 (25.7)
not answered 85 19 (22.3)
COPD
Yes 192 84 (43.8) 0.001
no 4,201 1,036 (24.1)
not answered 104 30 (28.8)
asthma or COPD
Yes 482 145 (30.1) 0.02
no 3,923 982 (25.1)
not answered 94 23 (24.5)
angina pectoris
Yes 314 55 (17.5) 0.001
no 4,078 1,072 (26.3)
not answered 105 23 (25.3)
MI
Yes 238 53 (22.3) 0.2
no 4,168 1,076 (25.8)
not answered 91 21 (23.1)
ChD (angina or infarction)
Yes 442 84 (19.0) 0.001
no 3,962 1,046 (26.4)
not answered 93 20 (21.5)
Diabetes
Yes 137 30 (21.9) 0.3
no 4,275 1,099 (25.7)
not answered 85 21 (24.7)
stroke
Yes 105 19 (18.1) 0.08
no 4,280 1,103 (25.8)
not answered 112 28 (25.0)
Notes: aStatistical significance of difference between subgroups, “not answered” 
excluded. bChi-square trend.
Abbreviations: MI, myocardial infarction; ChD, coronary heart disease.
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Results
A total of 4,631 subjects participated in both the fifth and 
the sixth surveys of the Tromsø study, and 4,497 subjects 
comprising 1,852 men and 2,645 women answered the 
questions on smoking in both surveys. The mean time dif-
ference between attending the two surveys was 6.2 years 
(standard deviation 0.5 years). The mean age at Tromsø 
5 was 61.1 years (range 30–81 years); 1,150 (25.6%) 
reported daily smoking and 1,753 (39.0%) reported former 
smoking. The highest prevalence of smoking (43.8%) 
was found in subjects with self-reported COPD, whereas 
the frequency among those with self-reported CHD was 
19.0%. The characteristics of the population in Tromsø 
5 and the respective frequencies of smoking are listed in 
Table 1.
In the sixth survey, 765 subjects (17.0%) reported current 
smoking, and 428 of the 1,150 who had been smoking in 
Tromsø 5 had quit (37.2%). A significantly higher quitting 
rate was found in men compared to women, and the quitting 
rate increased with the length of education. Self-reported 
diseases registered in Tromsø 5 had no significant impact 
on the quitting rate (Table 2). The number of days between 
attending the two surveys had no impact on the quitting rate 
(odds ratio =1, P=0.8).
Table 3 shows the frequencies of new self-reported 
diseases reported in Tromsø 6, but not in Tromsø 5, and 
the association between a new diagnosis and smoking ces-
sation. New diagnoses of asthma/COPD (n=79) and CHD 
(n=73) were both associated with increased frequency of 
quitting, 50.6% (P=0.01) and 52.1% (P=0.008), respec-
tively. A new diagnosis of asthma/COPD or CHD was 
reported in 144 subjects. Both men and women belonging 
to any of these diagnostic groups showed increased quit-
ting rates, 54.9% vs 39.8% (P=0.02) in men and 47.1% vs 
32.7% (P=0.009) in women. The impact of getting these 
new diagnoses was particularly strong among the subjects 
with education length no longer than 12 years (P=0.001; 
Figure 1). Subjects with education length up to 12 years 
were also more frequently diagnosed with these diseases 
compared to those with higher education, 16.0% and 
9.5% (P=0.01), respectively. Among subjects with higher 
education, a high quitting rate was independent of a new 
diagnosis (Figure 1).
A new diagnosis of both CHD and obstructive lung 
disease was significantly associated with smoking cessation 
when analyzed by logistic regression and also after adjusting 
for sex and education level in multivariable logistic regres-
sion analyses (Table 4).
Discussion
Main findings
Half of the participants with a new diagnosis of asthma/
COPD or angina/MI quit smoking during the 6 years of 
follow-up. However, the association between these new diag-
noses and smoking cessation was found only in participants 
Table 2 smoking cessation between 2001–2002 (Tromsø 5) 
and 2007–2008 (Tromsø 6) according to characteristics of 1,150 
smoking participants in Tromsø 5
n Quit smoking, n (%) P-valuea
sex
Men 462 194 (42.0) 0.006
Women 688 234 (34.0)
age (years)
30–49 233 87 (37.7) 0.6b
50–69 773 292 (37.8)
70–81 144 49 (34.0)
education
0–12 years 869 300 (34.5) 0.001b
13–16 years 168 74 (44.0)
16 years 75 42 (56.0)
not answered 38 12 (31.6)
self-reported diseases
asthma
Yes 91 26 (28.6) 0.8
no 1,040 394 (37.9)
not answered 19 6 (31.6)
COPD
Yes 84 35 (41.7) 0.4
no 1,036 384 (37.1)
not answered 30 9 (30.0)
asthma or COPD
Yes 145 51 (35.2) 0.5
no 982 371 (37.8)
not answered 23 6 (26.1)
angina pectoris
Yes 55 17 (30.9) 0.3
no 1,072 402 (37.5)
not answered 23 9 (39.1)
MI
Yes 53 17 (32.1) 0.4
no 1,076 403 (37.5)
not answered 21 8 (38.1)
ChD (angina or infarction)
Yes 84 28 (33.3) 0.3
no 1,046 392 (37.5)
not answered 20 8 (40.0)
Diabetes
Yes 30 7 (23.3) 0.1
no 1,099 412 (37.5)
not answered 21 9 (42.9)
stroke
Yes 19 6 (31.6) 0.6
no 1,103 412 (37.4)
not answered 28 10 (35.7)
Notes: aStatistical significance of difference between subgroups, “not answered” 
excluded. bChi-square trend.
Abbreviations: MI, myocardial infarction; ChD, coronary heart disease.
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smoking was strongly related to serum thiocyanate if the 
question was asked in a neutral setting.16 Although the 
questions on smoking were included in a self-administered 
questionnaire, underreporting of daily smoking among those 
with a new diagnosis cannot be ruled out.
All diagnoses were self-reported, and their correctness 
could not be confirmed. Shift in diagnosis based on the same 
illness from Tromsø 5 to Tromsø 6, for instance, between 
asthma and COPD, may have taken place in some subjects. 
Such a change has been counted as a new diagnosis. This is 
no longer a problem when asthma and COPD are combined 
into one category (asthma and/or COPD) and subjects with 
a new diagnosis of any of these diseases are compared with 
those with neither of the diagnoses at both Tromsø 5 and 
Tromsø 6.
Although we have found associations between a new 
diagnosis and smoking cessation, we do not know for sure 
whether the extra cessations in the subgroups with a new 
diagnosis were really preceded by a new diagnosis. Subjects 
in these subgroups could have stopped smoking before the 
diagnosis was given. In these cases, it is likely that symptoms 
from a pulmonary or heart disease had raised their awareness 
of the risk of continued smoking.
Comparisons with previous studies
No previous study has, to our knowledge, described smoking 
cessation in relation to a new diagnosis of heart or lung 
disease. Most previous studies evaluated smoking cessation 
??
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? ????? ????? ????? ?????
????????????
????
????
???
???
??????????????????? ???????????????????
????
????
????
????
???? ????
???????????????????????????????????????????
??????????????????????????????????????????????
?????????????????????????????????????????????????
Figure 1 Percentage of participants who quit smoking between 2001–2002 (Tromsø 5) 
and 2007–2008 (Tromsø 6) among 1,064 participants, by education length, and heart 
and lung disease.
Table 3 smoking cessation between 2001–2002 (Tromsø 5) and 
2007–2008 (Tromsø 6) according to new diagnosis in the same 
period
n Quit smoking, n (%) P-valuea
new diagnosis
asthma
Yes 42 20 (47.6) 0.2
no 967 365 (37.7)
COPD
Yes 75 36 (48.0) 0.05
no 933 342 (36.7)
asthma or COPD
Yes 79 40 (50.6) 0.01
no 903 331 (36.7)
angina pectoris
Yes 33 15 (45.5) 0.3
no 1,017 379 (37.3)
MI
Yes 58 30 (51.7) 0.02
no 995 365 (36.7)
ChD (angina or infarction)
Yes 73 38 (52.1) 0.008
no 955 348 (36.4)
Diabetes
Yes 33 12 (34.4) 0.9
no 1,035 391 (37.8)
stroke
Yes 37 12 (32.4) 0.5
no 1,037 389 (37.5)
Notes: aStatistical significance of difference between participants with a new 
(possibly combined) diagnosis and participants without a new (possibly combined) 
diagnosis in Tromsø 5. In each analysis, participants who reported the diagnosis 
in question in Tromsø 5, and those who have not answered the question on the 
diagnosis in any of the surveys, have been excluded.
Abbreviations: MI, myocardial infarction; ChD, coronary heart disease.
with education length up to 12 years. The much higher 
smoking rate among those with asthma and, in particular, 
those with COPD at baseline than in those with CHD indi-
cates a shift in attitude toward smoking cessation among 
subjects with COPD.
strengths and limitations
The high number of participants and the high attendance 
rates among those invited are strengths of the study. The 
prevalences of daily smoking among all the attendees in 
Tromsø 5 and Tromsø 6 were 31% and 22%, respectively,11 
which are close to the national prevalences of 29% and 
21%, as registered by Statistics Norway (https://www.ssb.
no)15 in 2002 and 2008, respectively. In our study sample, 
the prevalence was lower at both points of time, 25.6% and 
17.0%, respectively, and a healthy survivor effect may have 
contributed to the low frequency of daily smoking in our 
subsample. The study is based on questionnaires and not on 
objective measurements of smoking, such as cotinine and 
thiocyanate. In a previous Norwegian study, self-reported 
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Table 4 Ors for smoking cessation between Tromsø 5 (2001–2002) and Tromsø 6 (2007–2008) according to characteristics of 1,024 
smoking participants in Tromsø 5 and new diagnosis reported in Tromsø 6
Univariable Multivariable
OR (95% CI) P-value OR (95% CI) P-value
age 1.0 (1.0–1.0) 0.9 1.0 (1.0–1.0) 0.6
Male sex 1.4 (1.1–1.8) 0.01 1.4 (1.1–1.8) 0.02
education (years)
13–16 1.5 (1.0–2.1) 0.03 1.6 (1.1–2.2) 0.02
17 2.3 (1.4–3.8) 0.001 2.5 (1.5–4.1) 0.001
new diagnosis of ChD 1.7 (1.1–2.8) 0.02 1.7 (1.0–2.9) 0.04
new diagnosis of asthma or COPD 1.7 (1.1–2.6) 0.02 1.7 (1.1–2.7) 0.02
Abbreviations: Or, odds ratio; ChD, coronary heart disease.
programs, and control groups in such studies can be com-
pared with our participants. However, the quitting rate of 
41.7% among subjects with a COPD diagnosis reported in 
Tromsø 5 was more similar to the rate of 38% among the 
COPD patients, who had taken part in the smoking cessation 
program in a Swedish study, than the rate of 10% among 
the COPD patients on usual care.6 In a study from primary 
care, where smokers received smoking cessation advice and 
were followed up annually with spirometry, higher rates of 
abstinence were found among those with COPD than among 
those with normal lung function.17 This result is in line with 
our findings. We found that the quitting rate increased with 
increasing length of education, and this association is well 
known from previous studies.18
Qualitative studies have shown that patients with a COPD 
diagnosis may have several reasons for not quitting despite 
the knowledge of harming themselves,19 and they do not 
always believe that quitting would give them a better life.20 
COPD patients often show little interest in receiving help 
from medication and describe unassisted quitting as the best 
method to stop smoking, based on willpower, strong motiva-
tion, and internal strength.21 In our study, a new diagnosis 
of COPD or CHD might have given many participants the 
motivation they needed to quit without assistance. In another 
qualitative study, the interviewees who had stopped smoking 
emphasized that persons close to them had a strong influence 
on their decision to quit.22 This gives a reason to believe that 
the decreasing acceptance of smoking in the society also 
influences COPD patients.
Conclusion
It has been suggested that a hard core of smokers will con-
stitute an increasing proportion of COPD patients who still 
smoke.23 The high quitting rates among subjects with both an 
established and a new diagnosis of COPD in our study con-
tradicts this pessimism. The study supports pursuit of early 
diagnosis of COPD and gives reasons for a more optimistic 
attitude among health workers when they discuss smoking 
cessation with their COPD patients.
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